Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Statement: Zantac (ranitidine) litigation

28 Jun 2024 17:37

RNS Number : 4557U
GSK PLC
28 June 2024
 

Issued: 28 June 2024, London UK

 

Statement: Zantac (ranitidine) litigation - Gross case

 

 

GSK plc (LSE/NYSE: GSK) has reached a confidential settlement with Martin Gross resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.

 

Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.

 

GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

GSK enquiries

Media:

Tim Foley

+44 (0) 20 8047 5502

(London)

Dan Smith

+44 (0) 20 8047 5502

(London)

Kathleen Quinn

+1 202 603 5003

(Washington DC)

Lyndsay Meyer

+1 202 302 4595

(Washington DC)

 

Investor Relations:

Nick Stone

+44 (0) 7717 618834

(London)

James Dodwell

+44 (0) 20 8047 2406

(London)

Mick Readey

+44 (0) 7990 339653

(London)

Josh Williams

+44 (0) 7385 415719

(London)

Camilla Campbell

+44 (0) 7803 050238

(London)

Steph Mountifield

+44 (0) 7796 707505

(London)

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

Frannie DeFranco

+1 215 751 4855

(Philadelphia)

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q1 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STREAKKPADKLEFA
Date   Source Headline
1st Apr 20263:30 pmRNSDirector/PDMR Shareholding
1st Apr 20263:00 pmRNSTotal Voting Rights
1st Apr 20267:00 amRNSViiV completes changes to minority shareholding
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:05 amRNSBepirovirsen accepted for review in China
30th Mar 20267:00 amRNSExdensur approved for severe asthma in China
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSBepirovirsen accepted for review by the EMA
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20263:30 pmRNSDirector/PDMR Shareholding
25th Mar 20261:00 pmRNSNotice of AGM
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20263:30 pmRNSDirector/PDMR Shareholding
23rd Mar 20263:00 pmRNSAdmission to Trading
23rd Mar 20267:00 amRNSGSK Lung Cancer ADC Gets Japan Orphan Drug Status
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 202612:00 pmRNSLynavoy (linerixibat) approved by US FDA
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20263:30 pmRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 202610:31 amRNSUS FDA approves Arexvy for adults 18-49 AIR
13th Mar 202610:31 amRNSUS FDA approves Arexvy for adults 18-49 AIR
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20263:00 pmRNSBoard Committee Change
9th Mar 20263:00 pmRNSBoard Committee Change
9th Mar 20267:00 amRNSGSK and Alfasigma agree global linerixibat rights
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20262:21 pmRNSFiling of GSK plc 2025 Annual Report on Form 20-F
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 202610:00 amRNSGSK publishes Annual Report 2025
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20263:30 pmRNSDirector/PDMR Shareholding
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20263:00 pmRNSGSK completes acquisition of RAPT Therapeutics
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20263:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.